All In Biotech

Drug Trial Radar · NCT05950841

Safety and Effectiveness of IHAT in Iron Deficient Pre-menopausal Woman

A Randomised, Double-blind Study to Determine the Safety and Efficacy of IHAT in Iron Deficient Premenopausal Women.

Last checked: Nov 19, 2026Latest source record: Mar 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

180

Actual

Start

Mar 6, 2024

Primary completion

Feb 3, 2025

Study completion Feb 3, 2025

Sponsor

Lead sponsor
RDC Clinical Pty LtdIndustry
Sponsor type
Industry
Collaborators
Nemysis Ltd
First posted
Jul 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a double blind, randomised, placebo-controlled trial to evaluate orally-dosed IHAT (iron hydroxide adipate tartrate) at 2 different doses compared to placebo for increasing serum ferritin levels in iron-deficient but otherwise healthy premenopausal women over 12 weeks.

Conditions

  • Iron-deficiency

Interventions

  • Low dose IHATDrug

    Once daily dose of 1 capsule (100mg per capsule IHAT) and Once daily dose of 1 capsule (carob flour)

  • High Dose IHATDrug

    Twice daily dose of 1 capsule (100mg per capsule IHAT)

  • Carob flourDrug

    Twice daily dose of 1 capsule (carob flour)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of women recovering from ID at week 12Time frame: Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • RDC Clinical Pty Ltd

    New Farm, Queensland, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.